-
BPC-157
— RESEARCH PEPTIDE, 10mg / Vial, listed purity 99.8% (batch COA pending), £51.00
Body Protection Compound studied in in-vitro cytoprotection research.
-
TB-500
— RESEARCH PEPTIDE, 10mg / Vial, listed purity 99.6% (batch COA pending), £58.00
Thymosin Beta-4 fragment studied in in-vitro cell-migration research.
-
GHK-Cu
— PROTEIN REMODELING, 50mg / Vial, listed purity 99.6% (batch COA pending), £49.00
Copper tripeptide (GHK-Cu). Extracellular-matrix and protein-remodelling research.
-
GHK-Cu (Max)
— PROTEIN REMODELING, 100mg / Vial, listed purity 99.6% (batch COA pending), £55.00
High-concentration copper tripeptide. Advanced remodelling research.
-
Ara-290
— EPO-DERIVED PEPTIDE, 10mg / Vial, listed purity 99.5% (batch COA pending), £75.00
Erythropoietin-derived peptide (ARA-290). Innate-repair receptor-binding research.
-
BPC-157
— RESEARCH PEPTIDE, 5mg / Vial, listed purity 99.8% (batch COA pending), £44.00
Body Protection Compound studied in in-vitro cell-migration research.
-
BPC-157 / GHK-Cu / KPV / TB-500
— PEPTIDE BLEND, 10 + 50 + 10 + 10mg / Vial, listed purity 99.5% (batch COA pending), £176.00
Four-compound research blend — BPC-157, GHK-Cu, KPV and TB-500.
-
BPC-157 / GHK-Cu / TB-500
— PEPTIDE BLEND, 10 + 50 + 10mg / Vial, listed purity 99.5% (batch COA pending), £115.00
Three-compound research blend — BPC-157, GHK-Cu and TB-500.
-
BPC-157 / TB-500
— PEPTIDE BLEND, 5 + 5mg / Vial, listed purity 99.6% (batch COA pending), £60.00
Two-compound research blend — BPC-157 and TB-500.
-
BPC-157 / TB-500
— PEPTIDE BLEND, 10 + 10mg / Vial, listed purity 99.6% (batch COA pending), £70.00
Two-compound research blend (high-dose) — BPC-157 and TB-500.
-
KPV
— RESEARCH PEPTIDE, 10mg / Vial, listed purity 99.6% (batch COA pending), £67.00
Alpha-MSH C-terminal tripeptide studied in vitro.
-
LL-37
— RESEARCH PEPTIDE, 5mg / Vial, listed purity 99.5% (batch COA pending), £75.00
Cathelicidin peptide studied in in-vitro antimicrobial research.